Loading…
Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism
Recent studies have revealed that the immunological function of leukocytes is dependent on their cellular metabolism, and some researchers have advocated the beneficial effects of pioglitazone against sepsis in young mice, although bacterial infections are more prevalent in elderly hosts. Here, we i...
Saved in:
Published in: | Innate immunity (London, England) England), 2019-08, Vol.25 (6), p.356-368 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3 |
---|---|
cites | cdi_FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3 |
container_end_page | 368 |
container_issue | 6 |
container_start_page | 356 |
container_title | Innate immunity (London, England) |
container_volume | 25 |
creator | Nakashima, Masahiro Kinoshita, Manabu Nakashima, Hiroyuki Kotani, Aya Ishikiriyama, Takuya Kato, Shoichiro Hiroi, Sadayuki Seki, Shuhji |
description | Recent studies have revealed that the immunological function of leukocytes is dependent on their cellular metabolism, and some researchers have advocated the beneficial effects of pioglitazone against sepsis in young mice, although bacterial infections are more prevalent in elderly hosts. Here, we investigated pioglitazone’s preventative effect against sepsis induced by intravenous injection of a lethal dose of Escherichia coli in elderly mice (50–60 wk old) and examined its immunological and metabolic effects on liver leukocytes. Pioglitazone improved bacterial elimination in the peripheral blood, lowered serum pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ), and prevented septic death. It also enhanced bacterial elimination in the liver, by increasing the phagocytic and bactericidal activities of liver F4/80+CD11b+ recruited macrophages (Mφ), their CD206 expression and reactive oxygen species production. Quantitative PCR revealed that pioglitazone treatment enhanced gene expression of rate-limiting enzymes for glycolysis in hepatic CD11b+ cells (including neutrophils and recruited Mφ), and their improved phagocytic and bactericidal activities were abolished by glycolysis inhibiting reagents. These findings present the possibility that pioglitazone strengthens the phagocytic and bactericidal activities of liver recruited Mφ and that these immunological activities are closely associated with their glucose catabolism. |
doi_str_mv | 10.1177/1753425919849620 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c4a650e6bfef4f12a5ead2c08cdbfe05</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1753425919849620</sage_id><doaj_id>oai_doaj_org_article_c4a650e6bfef4f12a5ead2c08cdbfe05</doaj_id><sourcerecordid>2313772357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3</originalsourceid><addsrcrecordid>eNp1kkuP1SAUgBujccbRvStD4sZNlUcpZWNiJj4mmUQXuiZADx1uaKnQ3qTu_OdyvePVmcQVcPjOBwdOVT0n-DUhQrwhgrOGcklk18iW4gfV-SFUN7QVD09zLs-qJznvMC4IF4-rM0awbDtKzqufX3wcgl_0jzgB8uOc4h4ymm_0EO22eIu0XfzeLxuKDgW_h4QS2LT6BXo0apvigS0pfkIQekhhQ6O3gOaYszdlZTZUrGNc_DSgIaw2ZkBWL9rE4PP4tHrkdMjw7Ha8qL59eP_18lN9_fnj1eW769py2Sx1h4FLIzH0vOHMYmKd5LwznHZMSGbaviPGcYOZA2EtkL7D1hlNJTTYgWUX1dXR20e9U3Pyo06bitqr34GYBqVTKTiAso1uOYbWOHCNI1Rz0D21uLN9CWFeXG-Prnk1I_QWpiXpcEd6d2fyN2qIeyUIZi1piuDVrSDF7yvkRY0-WwhBTxDXrChlFAsu6AF9eQ_dxTVN5akUZYQJQRkXhcJHqnxIzgnc6TIEq0OvqPu9UlJe_FvEKeFPcxSgPgK5fPDfU_8r_AVpn8uC</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2313772357</pqid></control><display><type>article</type><title>Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism</title><source>SAGE Open Access</source><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Nakashima, Masahiro ; Kinoshita, Manabu ; Nakashima, Hiroyuki ; Kotani, Aya ; Ishikiriyama, Takuya ; Kato, Shoichiro ; Hiroi, Sadayuki ; Seki, Shuhji</creator><creatorcontrib>Nakashima, Masahiro ; Kinoshita, Manabu ; Nakashima, Hiroyuki ; Kotani, Aya ; Ishikiriyama, Takuya ; Kato, Shoichiro ; Hiroi, Sadayuki ; Seki, Shuhji</creatorcontrib><description>Recent studies have revealed that the immunological function of leukocytes is dependent on their cellular metabolism, and some researchers have advocated the beneficial effects of pioglitazone against sepsis in young mice, although bacterial infections are more prevalent in elderly hosts. Here, we investigated pioglitazone’s preventative effect against sepsis induced by intravenous injection of a lethal dose of Escherichia coli in elderly mice (50–60 wk old) and examined its immunological and metabolic effects on liver leukocytes. Pioglitazone improved bacterial elimination in the peripheral blood, lowered serum pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ), and prevented septic death. It also enhanced bacterial elimination in the liver, by increasing the phagocytic and bactericidal activities of liver F4/80+CD11b+ recruited macrophages (Mφ), their CD206 expression and reactive oxygen species production. Quantitative PCR revealed that pioglitazone treatment enhanced gene expression of rate-limiting enzymes for glycolysis in hepatic CD11b+ cells (including neutrophils and recruited Mφ), and their improved phagocytic and bactericidal activities were abolished by glycolysis inhibiting reagents. These findings present the possibility that pioglitazone strengthens the phagocytic and bactericidal activities of liver recruited Mφ and that these immunological activities are closely associated with their glucose catabolism.</description><identifier>ISSN: 1753-4259</identifier><identifier>EISSN: 1753-4267</identifier><identifier>DOI: 10.1177/1753425919849620</identifier><identifier>PMID: 31096821</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aging ; Animals ; Bacteria ; CD11b antigen ; CD11b Antigen - metabolism ; Cytokines - metabolism ; Escherichia coli - physiology ; Escherichia coli Infections - drug therapy ; Gene expression ; Glucose - metabolism ; Glycolysis ; Immunology ; Inflammation ; Inflammation Mediators - metabolism ; Interleukin 12 ; Intravenous administration ; Lethal dose ; Leukocytes (neutrophilic) ; Liver ; Liver - pathology ; Macrophages ; Macrophages - drug effects ; Macrophages - immunology ; Male ; Mice ; Mice, Inbred C57BL ; Original ; Peripheral blood ; Phagocytes ; Phagocytosis ; Pioglitazone ; Pioglitazone - pharmacology ; Pioglitazone - therapeutic use ; PPAR gamma - agonists ; Reactive oxygen species ; Reactive Oxygen Species - metabolism ; Sepsis ; Sepsis - drug therapy ; Tumor necrosis factor-α ; γ-Interferon</subject><ispartof>Innate immunity (London, England), 2019-08, Vol.25 (6), p.356-368</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2019 2019 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3</citedby><cites>FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3</cites><orcidid>0000-0003-4385-5802</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103614/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2313772357?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,21965,25752,27852,27923,27924,37011,37012,44589,44944,45332,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31096821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakashima, Masahiro</creatorcontrib><creatorcontrib>Kinoshita, Manabu</creatorcontrib><creatorcontrib>Nakashima, Hiroyuki</creatorcontrib><creatorcontrib>Kotani, Aya</creatorcontrib><creatorcontrib>Ishikiriyama, Takuya</creatorcontrib><creatorcontrib>Kato, Shoichiro</creatorcontrib><creatorcontrib>Hiroi, Sadayuki</creatorcontrib><creatorcontrib>Seki, Shuhji</creatorcontrib><title>Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism</title><title>Innate immunity (London, England)</title><addtitle>Innate Immun</addtitle><description>Recent studies have revealed that the immunological function of leukocytes is dependent on their cellular metabolism, and some researchers have advocated the beneficial effects of pioglitazone against sepsis in young mice, although bacterial infections are more prevalent in elderly hosts. Here, we investigated pioglitazone’s preventative effect against sepsis induced by intravenous injection of a lethal dose of Escherichia coli in elderly mice (50–60 wk old) and examined its immunological and metabolic effects on liver leukocytes. Pioglitazone improved bacterial elimination in the peripheral blood, lowered serum pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ), and prevented septic death. It also enhanced bacterial elimination in the liver, by increasing the phagocytic and bactericidal activities of liver F4/80+CD11b+ recruited macrophages (Mφ), their CD206 expression and reactive oxygen species production. Quantitative PCR revealed that pioglitazone treatment enhanced gene expression of rate-limiting enzymes for glycolysis in hepatic CD11b+ cells (including neutrophils and recruited Mφ), and their improved phagocytic and bactericidal activities were abolished by glycolysis inhibiting reagents. These findings present the possibility that pioglitazone strengthens the phagocytic and bactericidal activities of liver recruited Mφ and that these immunological activities are closely associated with their glucose catabolism.</description><subject>Aging</subject><subject>Animals</subject><subject>Bacteria</subject><subject>CD11b antigen</subject><subject>CD11b Antigen - metabolism</subject><subject>Cytokines - metabolism</subject><subject>Escherichia coli - physiology</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Gene expression</subject><subject>Glucose - metabolism</subject><subject>Glycolysis</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Inflammation Mediators - metabolism</subject><subject>Interleukin 12</subject><subject>Intravenous administration</subject><subject>Lethal dose</subject><subject>Leukocytes (neutrophilic)</subject><subject>Liver</subject><subject>Liver - pathology</subject><subject>Macrophages</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - immunology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Original</subject><subject>Peripheral blood</subject><subject>Phagocytes</subject><subject>Phagocytosis</subject><subject>Pioglitazone</subject><subject>Pioglitazone - pharmacology</subject><subject>Pioglitazone - therapeutic use</subject><subject>PPAR gamma - agonists</subject><subject>Reactive oxygen species</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Sepsis</subject><subject>Sepsis - drug therapy</subject><subject>Tumor necrosis factor-α</subject><subject>γ-Interferon</subject><issn>1753-4259</issn><issn>1753-4267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kkuP1SAUgBujccbRvStD4sZNlUcpZWNiJj4mmUQXuiZADx1uaKnQ3qTu_OdyvePVmcQVcPjOBwdOVT0n-DUhQrwhgrOGcklk18iW4gfV-SFUN7QVD09zLs-qJznvMC4IF4-rM0awbDtKzqufX3wcgl_0jzgB8uOc4h4ymm_0EO22eIu0XfzeLxuKDgW_h4QS2LT6BXo0apvigS0pfkIQekhhQ6O3gOaYszdlZTZUrGNc_DSgIaw2ZkBWL9rE4PP4tHrkdMjw7Ha8qL59eP_18lN9_fnj1eW769py2Sx1h4FLIzH0vOHMYmKd5LwznHZMSGbaviPGcYOZA2EtkL7D1hlNJTTYgWUX1dXR20e9U3Pyo06bitqr34GYBqVTKTiAso1uOYbWOHCNI1Rz0D21uLN9CWFeXG-Prnk1I_QWpiXpcEd6d2fyN2qIeyUIZi1piuDVrSDF7yvkRY0-WwhBTxDXrChlFAsu6AF9eQ_dxTVN5akUZYQJQRkXhcJHqnxIzgnc6TIEq0OvqPu9UlJe_FvEKeFPcxSgPgK5fPDfU_8r_AVpn8uC</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Nakashima, Masahiro</creator><creator>Kinoshita, Manabu</creator><creator>Nakashima, Hiroyuki</creator><creator>Kotani, Aya</creator><creator>Ishikiriyama, Takuya</creator><creator>Kato, Shoichiro</creator><creator>Hiroi, Sadayuki</creator><creator>Seki, Shuhji</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8C1</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4385-5802</orcidid></search><sort><creationdate>20190801</creationdate><title>Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism</title><author>Nakashima, Masahiro ; Kinoshita, Manabu ; Nakashima, Hiroyuki ; Kotani, Aya ; Ishikiriyama, Takuya ; Kato, Shoichiro ; Hiroi, Sadayuki ; Seki, Shuhji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aging</topic><topic>Animals</topic><topic>Bacteria</topic><topic>CD11b antigen</topic><topic>CD11b Antigen - metabolism</topic><topic>Cytokines - metabolism</topic><topic>Escherichia coli - physiology</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Gene expression</topic><topic>Glucose - metabolism</topic><topic>Glycolysis</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Inflammation Mediators - metabolism</topic><topic>Interleukin 12</topic><topic>Intravenous administration</topic><topic>Lethal dose</topic><topic>Leukocytes (neutrophilic)</topic><topic>Liver</topic><topic>Liver - pathology</topic><topic>Macrophages</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - immunology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Original</topic><topic>Peripheral blood</topic><topic>Phagocytes</topic><topic>Phagocytosis</topic><topic>Pioglitazone</topic><topic>Pioglitazone - pharmacology</topic><topic>Pioglitazone - therapeutic use</topic><topic>PPAR gamma - agonists</topic><topic>Reactive oxygen species</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Sepsis</topic><topic>Sepsis - drug therapy</topic><topic>Tumor necrosis factor-α</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakashima, Masahiro</creatorcontrib><creatorcontrib>Kinoshita, Manabu</creatorcontrib><creatorcontrib>Nakashima, Hiroyuki</creatorcontrib><creatorcontrib>Kotani, Aya</creatorcontrib><creatorcontrib>Ishikiriyama, Takuya</creatorcontrib><creatorcontrib>Kato, Shoichiro</creatorcontrib><creatorcontrib>Hiroi, Sadayuki</creatorcontrib><creatorcontrib>Seki, Shuhji</creatorcontrib><collection>SAGE Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Public Health Database</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Innate immunity (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakashima, Masahiro</au><au>Kinoshita, Manabu</au><au>Nakashima, Hiroyuki</au><au>Kotani, Aya</au><au>Ishikiriyama, Takuya</au><au>Kato, Shoichiro</au><au>Hiroi, Sadayuki</au><au>Seki, Shuhji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism</atitle><jtitle>Innate immunity (London, England)</jtitle><addtitle>Innate Immun</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>25</volume><issue>6</issue><spage>356</spage><epage>368</epage><pages>356-368</pages><issn>1753-4259</issn><eissn>1753-4267</eissn><abstract>Recent studies have revealed that the immunological function of leukocytes is dependent on their cellular metabolism, and some researchers have advocated the beneficial effects of pioglitazone against sepsis in young mice, although bacterial infections are more prevalent in elderly hosts. Here, we investigated pioglitazone’s preventative effect against sepsis induced by intravenous injection of a lethal dose of Escherichia coli in elderly mice (50–60 wk old) and examined its immunological and metabolic effects on liver leukocytes. Pioglitazone improved bacterial elimination in the peripheral blood, lowered serum pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ), and prevented septic death. It also enhanced bacterial elimination in the liver, by increasing the phagocytic and bactericidal activities of liver F4/80+CD11b+ recruited macrophages (Mφ), their CD206 expression and reactive oxygen species production. Quantitative PCR revealed that pioglitazone treatment enhanced gene expression of rate-limiting enzymes for glycolysis in hepatic CD11b+ cells (including neutrophils and recruited Mφ), and their improved phagocytic and bactericidal activities were abolished by glycolysis inhibiting reagents. These findings present the possibility that pioglitazone strengthens the phagocytic and bactericidal activities of liver recruited Mφ and that these immunological activities are closely associated with their glucose catabolism.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31096821</pmid><doi>10.1177/1753425919849620</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-4385-5802</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1753-4259 |
ispartof | Innate immunity (London, England), 2019-08, Vol.25 (6), p.356-368 |
issn | 1753-4259 1753-4267 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_c4a650e6bfef4f12a5ead2c08cdbfe05 |
source | SAGE Open Access; Publicly Available Content (ProQuest); PubMed Central |
subjects | Aging Animals Bacteria CD11b antigen CD11b Antigen - metabolism Cytokines - metabolism Escherichia coli - physiology Escherichia coli Infections - drug therapy Gene expression Glucose - metabolism Glycolysis Immunology Inflammation Inflammation Mediators - metabolism Interleukin 12 Intravenous administration Lethal dose Leukocytes (neutrophilic) Liver Liver - pathology Macrophages Macrophages - drug effects Macrophages - immunology Male Mice Mice, Inbred C57BL Original Peripheral blood Phagocytes Phagocytosis Pioglitazone Pioglitazone - pharmacology Pioglitazone - therapeutic use PPAR gamma - agonists Reactive oxygen species Reactive Oxygen Species - metabolism Sepsis Sepsis - drug therapy Tumor necrosis factor-α γ-Interferon |
title | Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T00%3A12%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pioglitazone%20improves%20phagocytic%20activity%20of%20liver%20recruited%20macrophages%20in%20elderly%20mice%20possibly%20by%20promoting%20glucose%20catabolism&rft.jtitle=Innate%20immunity%20(London,%20England)&rft.au=Nakashima,%20Masahiro&rft.date=2019-08-01&rft.volume=25&rft.issue=6&rft.spage=356&rft.epage=368&rft.pages=356-368&rft.issn=1753-4259&rft.eissn=1753-4267&rft_id=info:doi/10.1177/1753425919849620&rft_dat=%3Cproquest_doaj_%3E2313772357%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c594t-80e59b90ed5453c01cf9558b5283793b6d81bf5b03fe7cce1d80cfba29e40fec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2313772357&rft_id=info:pmid/31096821&rft_sage_id=10.1177_1753425919849620&rfr_iscdi=true |